KIMS signs O&M deal for 250-bed Arete Hospitals in Hyderabad

Strategic Transactions View source PDF Explain this filing

KIMS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.3%Reaction day

₹788.00

prior close

₹794.60

announcement price

After-mkt

timing

Nifty Smallcap 250market+0.4%-1.7% vs market

Hospital peers, median of 26sector-0.5%-0.7% vs sector

On the reaction day the stock moved 1.7 pts less than Nifty Smallcap 250 and 0.7 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.3

10m

-0.7

15m

-0.6

30m

-0.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.3+0.4-1.7-0.5-0.7

Next day

-2.7+0.2-2.9+0.0-2.7

-2.1+0.0-2.1-0.2-1.9

-4.2+0.6-4.8+0.0-4.2

-2.5+0.5-3.1-1.0-1.6

-2.8+0.9-3.7-0.1-2.6

-3.2+0.1-3.3+0.2-3.4

15d

-2.6+0.0-2.6+0.8-3.4

+0.2-0.3+0.5+1.1-0.9

-14.8-7.1-7.8-12.7-2.2

—————

UpDownMarket · Nifty Smallcap 250Sector · Hospital peers, median of 26Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

KIMS has entered into an Operations and Management Agreement with Aurevia Hospitals to run Arete Hospitals, a 250-bed multispecialty hospital in Gachibowli, Hyderabad. The agreement is for 5 years, extendable by another 5 years, on an exclusive basis. KIMS will earn 9 percent of Net Revenue as management fee. KIMS also secured a Call Option giving it the right (not obligation) to acquire the hospital later at terms to be decided. AHPL acquired Arete via Business Transfer Agreement on 03 July 2026. The deal is not a related party transaction.

Likely market impact

Expands KIMS presence in Hyderabad's growing healthcare market. Call option offers future acquisition route. Revenue impact modest at 9 percent fee share.